69P - CD200 and indoleamine 2,3-dioxygenase-1 (IDO-1) overexpresion in relapsed acute myeloid leukemia patients

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Leukaemia
Haematologic Malignancies
Presenter Ali Memarian
Citation Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361
Authors A. Memarian1, S. Abdolmaleki2, M. Mirahmadian2, M. Jeddi-Tehrani3
  • 1Stem Cell Research Center, Golestan University of Medical Sciences, 49189-36316 - Gorgan/IR
  • 2Department Of Immunology, Tehran University of Medical Sciences, Tehran/IR
  • 3Monoclonal Antibody Research Center, Avicenna Research Institute, Tehran/IR

Abstract

Background

Immunosuppression is one of the major causes of AML pathogenesis and progression. CD200 and IDO are immunoregulatory factors which overexpressed in some solid tumors and hematological malignancies. Distinct researches have shown CD200 and IDO expression is associated with AML progression. In the current study, we simultaneously examined the expression of these molecules, as the two important factors including in immunosuppression, in the newly diagnosed and relapse AML patients to investigate their correlation with each other.

Methods

48 PBMC samples of newly diagnosed and relapse AML patients were tested and also 32 normal subjects were employed as control. CD200 expression level was examined on cells by Flow cytometry and quantitative real time RT-PCR was used to determine the IDO-1 gene expression. Finally, data were analyzed statistically.

Results

Data showed that CD200 and IDO-1 overexpressed especially in relapsed patients. Comparison between FAB AML subgroups demonstrated no statistical differences in the case of CD200 level but expression of IDO-1 was slightly increased only in M4 subgroup in comparison to M3. Correlation analyses showed strong association between expression of CD200 and IDO-1 in all patients particularly in relapsed AML, whereas no significant correlation was found in normal subjects.

Conclusions

According to the role and overexpression of CD200 and IDO-1 in AML patients and also their two-way correlation with T-regs in disease induction and progression, simultaneous assessment of these parameters are so valuable for more exact prognosis detection. Also inhibition of all these immunoregulatory pathways could be so useful for immunotherapy outcome, especially in relapsed AML.

Clinical trial identification

Legal entity responsible for the study

Tehran University of Medical Sciences

Funding

None

Disclosure

All authors have declared no conflicts of interest.